Lutetium Lu-177 vipivotide tetraxetan
- Generic Name
- Lutetium Lu-177 vipivotide tetraxetan
- Brand Names
- Pluvicto
- Drug Type
- Small Molecule
- Chemical Formula
- C49H68LuN9O16
- CAS Number
- 1703749-62-5
- Unique Ingredient Identifier
- G6UF363ECX
- Background
Lutetium Lu-177 vipivotide tetraxetan is a radioligand therapeutic agent. It consists of a radionuclide, lutetium Lu-177, linked to a moiety that binds to PSMA, a transmembrane protein that is expressed in prostate cancer.
...
- Indication
Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
- Associated Conditions
- Metastatic Castration-Resistant Prostate Cancer (mCRPC), Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Associated Therapies
- -
177Lu-PSMA-617 Managed Access Program for mCRPC Patients
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Advanced Accelerator Applications
- Registration Number
- NCT04825652
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC
- Conditions
- Interventions
- First Posted Date
- 2021-01-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1148
- Registration Number
- NCT04720157
- Locations
- 🇺🇸
Mayo Clinic - Arizona Mayo Clinic Hospital, Scottsdale, Arizona, United States
🇺🇸University of California San Diego - Moores Cancer Center, La Jolla, California, United States
🇺🇸VA Greater LA Healthcare System, Los Angeles, California, United States
177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-30
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 469
- Registration Number
- NCT04689828
- Locations
- 🇺🇸
Beth Israel Deaconess Med Ctr Dept. of BIDMC, Boston, Massachusetts, United States
🇺🇸Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸Univ of Florida College of Medicine x, Gainesville, Florida, United States
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 200
- Registration Number
- NCT04663997
- Locations
- 🇨🇦
Tom Baker Cancer Centre, Calgary, Alberta, Canada
🇨🇦BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦University Health Network, Toronto, Ontario, Canada
Lutetium-177-PSMA-617 in Oligo-metastatic Hormone Sensitive Prostate Cancer
- First Posted Date
- 2020-06-23
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 58
- Registration Number
- NCT04443062
- Locations
- 🇨🇾
German Oncology Center, Limassol, Cyprus
🇳🇱Amsterdam UMC, Amsterdam, Netherlands
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 20
- Registration Number
- NCT04430192
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 130
- Registration Number
- NCT04343885
- Locations
- 🇦🇺
Liverpool Hospital, Liverpool, New South Wales, Australia
🇦🇺St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺Royal North Shore, St Leonards, New South Wales, Australia
177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC
- Conditions
- Interventions
- First Posted Date
- 2018-06-04
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 6
- Registration Number
- NCT03545165
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-04-30
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Endocyte
- Target Recruit Count
- 831
- Registration Number
- NCT03511664
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇨🇦Sunnybrook Research Institute, Odette Cancer Center, Toronto, Ontario, Canada
Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC
- Conditions
- Interventions
- First Posted Date
- 2017-02-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 50
- Registration Number
- NCT03042468
- Locations
- 🇺🇸
Weill Cornell Medical College, New York, New York, United States
🇺🇸Tulane Cancer Center Clinic, New Orleans, Louisiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.